Roivant Sciences Ltd.

Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies. Its pipeline includes several product candidates targeting autoimmune and cardiopulmonary diseases. Key candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn for IgG-mediated autoimmune indications such as Graves' disease, rheumatoid arthritis, Sjögren's disease, myasthenia gravis, and cutaneous lupus erythematosus. Another candidate is mosliciguat, an inhaled soluble guanylate cyclase (sGC) activator for pulmonary hypertension associated with interstitial lung disease. The company also develops batoclimab for thyroid eye disease and brepocitinib, a TYK2/JAK1 inhibitor for dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis. Additionally, Roivant has delivery platforms including lipid nanoparticle (LNP) and ligand conjugate technologies.

Roivant Sciences Ltd. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ROIV. Its shares trade in US Dollars (USD). The company is headquartered in London, United Kingdom, but its primary listing is on a US exchange, making it accessible to global investors. The use of USD as the trading currency aligns with its US exchange listing, facilitating investment from US-based and international investors.

Roivant Sciences operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing innovative therapies for autoimmune and cardiopulmonary diseases. Biotechnology companies like Roivant typically engage in research and development of drugs based on biological processes, often involving monoclonal antibodies, small molecule inhibitors, and advanced delivery systems. The company's pipeline includes both monoclonal antibodies (e.g., IMVT-1402, batoclimab) and small molecule inhibitors (e.g., brepocitinib), reflecting a diverse approach within the biotech space.

Roivant Sciences Ltd. is headquartered in London, United Kingdom, and its primary market focus is the United States, as indicated by its Nasdaq listing and US dollar trading. The company operates as a clinical-stage entity, meaning its products are not yet commercially available; however, its development programs target global markets for autoimmune and cardiopulmonary diseases. The company's research and development efforts are directed toward indications that affect patients worldwide, including conditions like rheumatoid arthritis, myasthenia gravis, and pulmonary hypertension. While headquartered in the UK, Roivant's operations and clinical trials likely span multiple countries, leveraging its US listing for capital access.

Roivant Sciences has a pipeline of clinical-stage product candidates addressing autoimmune and cardiopulmonary diseases. Lead candidate mosliciguat is an inhaled sGC activator for pulmonary hypertension associated with interstitial lung disease. IMVT-1402 is a fully human monoclonal antibody targeting FcRn for multiple IgG-mediated autoimmune indications, including Graves' disease, rheumatoid arthritis, Sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus. Batoclimab is another monoclonal antibody for thyroid eye disease. Brepocitinib is a potent small molecule inhibitor of TYK2 and JAK1 for dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis. The company also has delivery platforms: a lipid nanoparticle (LNP) platform and a ligand conjugate platform, which may enable future therapies.